 |
N-acetylprocainamide |
|---|---|
| Trade Name | Napa |
| Orphan Indication | To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device |
| USA Market Approval | USA |
| USA Designation Date | 1990-03-23 00:00:00 |
| Sponsor | Medco Research, Inc.;8455 Beverly Blvd., Suite 308;Los Angeles, California, 90048 |
